Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.

26 (UPI) --Eli Lilly announced plans for four new pharmaceutical ... March 5 (UPI) -- U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized ...

Feb 20 - Eli ... pain. Buoyed by transformative products like Mounjaro and Zepbound, which have spurred a 60% sales surge and a 268% stock price rise over the past three years, Lilly plans to ...

Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer's. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets. These are the ...